Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
Compounds were synthesized using a facile
2019-08-06
Compounds were synthesized using a facile 8-step convergent synthesis ( and ). Briefly, (Boc)cyclen (compound ) was coupled using TBTU to Fmoc- or Cbz-protected amino alkyl acids (–), followed by deprotection using 20% piperidine in DMF, or H on Pd/C, respectively (–) (). Deprotected linkers were co
-
Programmed cellular death or apoptosis
2019-08-06
Programmed cellular death or apoptosis is a process genetically controlled that plays an important role in cellular homeostasis, being an important defense mechanism to remove cells that have been infected, damaged or mutated (Smith and Smith, 2012, Wlodkowic et al., 2011). Nevertheless, apoptosis s
-
Similarly synthetic analogs of Alogliptin by replacing the c
2019-08-06
Similarly synthetic analogs of Alogliptin by replacing the cyanobenzyl group with the butynyl group have been synthesized and tested as selective DPP-4 inhibitors [7], [8]. Additionally, quinazolines [9], [10], pyridopyrimidinediones [11], pyrazolopyrimidinones [12] and pyrimidines [13] as DPP-IV in
-
Taking a pragmatic approach with a view
2019-08-06
Taking a pragmatic approach with a view to complete the study and because chemotherapy regimens in NETs are not standardized, we do not impose a specific regimen in both arms. However, one regimen in each arm is recommended in order to reduce heterogeneity: the ALKY-based chemotherapy arm will recei
-
br Methods Adult male B CRHtklee mice g
2019-08-06
Methods Adult male B6, 129 CRHtklee mice (25–30g at the beginning of the experiments) that were wild-type (CRF1R+/+) and recessive homozygous or knockout (CRF1R−/−) were housed six per cage. Mice were 3–5months old and derived from mating CRF1R+/− breeders (Jackson Laboratory, California). Wild-t
-
Docking experiments showed that Me MeGlcA Xyl and MeGlc
2019-08-06
Docking experiments showed that Me-MeGlcA3Xyl4 and MeGlc3Xyl4 were bound to EcXyn30A and the R293A variant in the same way as MeGlcA3Xyl4, having MeGlcA or its modified forms accommodated in the -2b subsite. All ligands were coordinated by the same gtpase and no new interactions were observed. The o
-
It is well known that acrolein a metabolite of
2019-08-06
It is well known that acrolein, a metabolite of cyclophosphamide, is responsible for the cyclophosphamide-induced cystitis, and that acrolein is capable of activating TRPA1 channels expressed in the capsaicin-sensitive primary afferents [2], [11]. In this context, it is likely that the early phase o
-
Plasminogen is composed of five N terminal kringle
2019-08-06
Plasminogen is composed of five N-terminal kringle domains and a C-terminal serine protease domain. The kringle domains have an affinity to lysine and binding of plasminogen with its receptors is dependent on its lysine interacting kringle domains [10], [28]. In the current report, we show that enol
-
This relative lack of ET expression in highly
2019-08-06
This relative lack of ET-1 expression in highly malignant epithelial Linezolid could be explained by marked cellular anaplasia and cellular dysfunction; we also suggest that the high levels of VEGF, which have been evidenced in highly malignant mammary tumours (Restucci et al., 2002) may suppress E
-
Moving forward the new mathematical model opens doors for un
2019-08-06
Moving forward, the new mathematical model opens doors for understanding the SCF network, where activity of a component is blunted through mutation or altered in expression in diseased states, and during therapeutic intervention. Computational modeling could reveal underappreciated secondary or tert
-
br Acknowledgments The authors thank Dr
2019-08-06
Acknowledgments The authors thank Dr. Tai-Sheng Cheng, Yu-Wen Huang and Ting-Wei Gau for technical assistance. This work was supported by the National Science Council of TaiwanNSC 98-2320-B-024-002-MY3 and National University of TainanAB102-216. This information is available free of charge via th
-
Introduction Determining how genes function together
2019-08-06
Introduction Determining how genes function together as biological systems is a defining challenge of the genomic era. While genome sequences reveal the DNA blueprint of organisms, deciphering how this blueprint leads to biological function is challenging due in large part to the complexity of prot
-
In conclusion we have found that Egr can play an
2019-08-06
In conclusion, we have found that Egr1 can play an inhibitory role on DBH promoter-driven transcription. This inhibition requires a newly identified Egr1 response zd 14 at the −227/−224 region of DBH promoter. This inhibition appears to result from Egr1 directly bound to the DBH promoter. We specul
-
Valproic acid VPA is a first
2019-08-06
Valproic WIN 64338 hydrochloride (VPA) is a first-line treatment for epilepsy and bipolar disorder, although its therapeutic mechanism of action is not fully understood. Considerable evidence suggests that VPA can act through the GABAergic system, NMDA receptors, and/or sodium channels (for review,
-
Activating GSK signaling to inhibit
2019-08-05
Activating GSK3β signaling to inhibit PK signaling during ischemia/reperfusion (I/R) is protective of WM ischemic injury. Glycogen synthase kinase (GSK3), which was the first substrate identified for AKT [44], is inhibited by AKT phosphorylation at positions S9 and S21 [45]. When GSK3β is active, it
15540 records 954/1036 page Previous Next First page 上5页 951952953954955 下5页 Last page